Denali Therapeutics Inc. (NASDAQ:DNLI) Expected to Post Earnings of -$0.42 Per Share


Share on StockTwits

Wall Street brokerages predict that Denali Therapeutics Inc. (NASDAQ:DNLI) will report earnings per share (EPS) of ($0.42) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Denali Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.05). Denali Therapeutics posted earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings report on Friday, August 6th.

On average, analysts expect that Denali Therapeutics will report full year earnings of ($1.46) per share for the current fiscal year, with EPS estimates ranging from ($2.69) to $0.02. For the next financial year, analysts anticipate that the business will post earnings of ($2.15) per share, with EPS estimates ranging from ($3.12) to ($1.17). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Sunday, May 2nd. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.24). The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $31.62 million. Denali Therapeutics had a negative net margin of 968.59% and a negative return on equity of 39.19%. Denali Therapeutics’s revenue for the quarter was up 119.4% on a year-over-year basis.

DNLI has been the topic of a number of analyst reports. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating and set a $105.00 price objective on the stock in a research report on Wednesday, February 10th. Zacks Investment Research raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 price objective on the stock in a research report on Friday, February 19th. HC Wainwright lifted their price objective on shares of Denali Therapeutics from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a research note on Friday, January 8th. They issued a “positive” rating for the company. Finally, TheStreet upgraded shares of Denali Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $74.63.

Shares of Denali Therapeutics stock traded down $2.69 on Tuesday, reaching $55.62. The stock had a trading volume of 727,261 shares, compared to its average volume of 570,040. The company has a 50 day moving average price of $56.82 and a 200 day moving average price of $64.76. Denali Therapeutics has a 1 year low of $21.41 and a 1 year high of $93.94. The stock has a market capitalization of $6.74 billion, a P/E ratio of -25.17 and a beta of 2.00.

In related news, COO Alexander O. Schuth sold 10,000 shares of the business’s stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $67.84, for a total value of $678,400.00. Following the completion of the transaction, the chief operating officer now directly owns 10,686 shares in the company, valued at approximately $724,938.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Alexander O. Schuth sold 1,468 shares of the business’s stock in a transaction on Tuesday, February 9th. The shares were sold at an average price of $74.80, for a total transaction of $109,806.40. Following the completion of the transaction, the chief operating officer now owns 10,686 shares of the company’s stock, valued at $799,312.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,449,495 shares of company stock valued at $158,540,085. Company insiders own 19.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its holdings in Denali Therapeutics by 180.1% in the 4th quarter. US Bancorp DE now owns 395 shares of the company’s stock worth $33,000 after acquiring an additional 254 shares in the last quarter. Exchange Traded Concepts LLC purchased a new stake in Denali Therapeutics in the 4th quarter worth $42,000. HM Payson & Co. purchased a new stake in Denali Therapeutics in the 3rd quarter worth $45,000. Meeder Asset Management Inc. purchased a new stake in Denali Therapeutics in the 1st quarter worth $139,000. Finally, Bartlett & Co. LLC purchased a new stake in Denali Therapeutics in the 4th quarter worth $168,000. 68.15% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

See Also: How does a 12b-1 fee affect fund performance?

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.